| Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer DA Wick, JR Webb, JS Nielsen, SD Martin, DR Kroeger, K Milne, ... Clinical Cancer Research 20 (5), 1125-1134, 2014 | 172 | 2014 |
| Low mutation burden in ovarian cancer may limit the utility of neoantigen-targeted vaccines SD Martin, SD Brown, DA Wick, JS Nielsen, DR Kroeger, ... PloS one 11 (5), e0155189, 2016 | 140 | 2016 |
| Profound elevation of CD8+ T cells expressing the intraepithelial lymphocyte marker CD103 (αE/β7 Integrin) in high-grade serous ovarian cancer JR Webb, DA Wick, JS Nielsen, E Tran, K Milne, E McMurtrie, BH Nelson Gynecologic oncology 118 (3), 228-236, 2010 | 75 | 2010 |
| Profound CD8+ T cell immunity elicited by sequential daily immunization with exogenous antigen plus the TLR3 agonist poly(I:C) DA Wick, SD Martin, BH Nelson, JR Webb Vaccine 29 (5), 984-993, 2011 | 65 | 2011 |
| Conversion of tyrosine to the inflammation-associated analog 3′-nitrotyrosine at either TCR-or MHC-contact positions can profoundly affect recognition of the MHC class I … LL Hardy, DA Wick, JR Webb The Journal of Immunology 180 (9), 5956-5962, 2008 | 62 | 2008 |
| A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large … DA Wick, JR Webb Vaccine 29 (44), 7857-7866, 2011 | 55 | 2011 |
| Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer K Milne, RO Barnes, A Girardin, MA Mawer, NJ Nesslinger, A Ng, ... PloS one 3 (10), e3409, 2008 | 49 | 2008 |
| A library-based screening method identifies neoantigen-reactive T cells in peripheral blood prior to relapse of ovarian cancer SD Martin, DA Wick, JS Nielsen, N Little, RA Holt, BH Nelson Oncoimmunology 7 (1), e1371895, 2018 | 43 | 2018 |
| Polyfunctional T-cell responses are disrupted by the ovarian cancer ascites environment and only partially restored by clinically relevant cytokines E Tran, JS Nielsen, DA Wick, AV Ng, LDS Johnson, NJ Nesslinger, ... PLoS One 5 (12), e15625, 2010 | 37 | 2010 |
| Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma JS Nielsen, AR Chang, DA Wick, CG Sedgwick, Z Zong, AJ Mungall, ... Oncoimmunology 6 (7), e1321184, 2017 | 25 | 2017 |
| An in vitro-transcribed-mRNA polyepitope construct encoding 32 distinct HLA class I-restricted epitopes from CMV, EBV, and Influenza for use as a functional control in human … JS Nielsen, DA Wick, E Tran, BH Nelson, JR Webb Journal of immunological methods 360 (1-2), 149-156, 2010 | 20 | 2010 |
| Human papillomavirus E7 antigen compositions and uses thereof JR Webb, DA Wick US Patent App. 13/810,352, 2013 | 1 | 2013 |
| Research Highlights: Do conventional treatments for HPV-positive head and neck cancers elicit immunotherapeutic type responses? HA Kader, DA Wick, JR Webb Immunotherapy 3 (4), 469-473, 2011 | 1 | 2011 |
| Immunogenicity of recurrent mutations in MYD88 and EZH2 in non-Hodgkin lymphomas JS Nielsen, AR Chang, DA Wick, CG Sedgwick, Z Zong, AJ Mungall, ... Journal for ImmunoTherapy of Cancer 3, 1-1, 2015 | | 2015 |
| Abstract B19: Tumor-specific structural rearrangements as potential targets for anticancer vaccines. SD Martin, DA Wick, JR Webb, RA Holt, BH Nelson Cancer Research 73 (1_Supplement), B19-B19, 2013 | | 2013 |
| Human papillomavirus e7 antigen compositions and uses thereof JR Webb, DA Wick | | 2012 |
john webbBritish Columbia Cancer Agency / Deeley Research CentreVerified email at bccrc.ca
